Skip Navigation



Brain Advance Access published online on July 1, 2009

Brain, doi:10.1093/brain/awp163
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
132/9/2501    most recent
awp163v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bittner, S.
Right arrow Articles by Wiendl, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bittner, S.
Right arrow Articles by Wiendl, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2009). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system

Stefan Bittner1,*, Sven G. Meuth1,*, Kerstin Göbel1, Nico Melzer1, Alexander M. Herrmann1, Ole J. Simon1, Andreas Weishaupt1, Thomas Budde2, Douglas A. Bayliss3, Martin Bendszus4 and Heinz Wiendl1

1 University of Wuerzburg, Department of Neurology, Josef-Schneider-Str. 11, 97080 Wuerzburg, Germany 2 Westfaelische Wilhelms-University Muenster, Institute of Physiology, Robert-Koch Str. 27a, 48149 Muenster, Germany 3 University of Virginia, Department of Pharmacology, Charlottesville, Virginia 22908, USA 4 University of Heidelberg, Department of Neuroradiology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

Correspondence to: Sven G. Meuth, MD, PhD, University of Wuerzburg, Department of Neurology, Josef-Schneider-Str. 11, 97080 Wuerzburg, Germany E-mail: meuth_s{at}klinik.uni-wuerzburg.de Correspondence may also be addressed to: Heinz Wiendl, E-mail: heinz.wiendl{at}klinik.uni-wuerzburg.de

We provide evidence that TWIK-related acid-sensitive potassium channel 1 (TASK1), a member of the family of two-pore domain potassium channels relevant for setting the resting membrane potential and balancing neuronal excitability that is expressed on T cells and neurons, is a key modulator of T cell immunity and neurodegeneration in autoimmune central nervous system inflammation. After induction of experimental autoimmune encephalomyelitis, an experimental model mimicking multiple sclerosis, TASK1–/– mice showed a significantly reduced clinical severity and markedly reduced axonal degeneration compared with wild-type controls. T cells from TASK1–/– mice displayed impaired T cell proliferation and cytokine production, while the immune repertoire is otherwise normal. In addition to these effects on systemic T cell responses, TASK1 exhibits an independent neuroprotective effect which was demonstrated using both a model of acutely prepared brain slices cocultured with activated T cells as well as in vitro cultivation experiments with isolated optic nerves. Anandamide, an endogenous cannabinoid and inhibitor of TASK channels, reduced outward currents and inhibited effector functions of T cells (IFN-{gamma} production and proliferation); an effect completely abrogated in TASK1–/– mice. Accordingly, preventive blockade of TASK1 significantly ameliorated experimental autoimmune encephalomyelitis after immunization. Therapeutic application of anandamide significantly reduced disease severity and was capable of lowering progressive loss of brain parenchymal volume as assessed by magnetic resonance imaging. These data support the identification and characterization of TASK1 as potential molecular target for the therapy of inflammatory and degenerative central nervous system disorders.

Key Words: multiple sclerosis; EAE; TASK1; K2P; potassium channels

Abbreviations: AEA, arachidonylethanolamide; APC, antigen-presenting cells; AVD, apoptotic volume decrease; EAE, experimental autoimmune encephalomyelitis; CST, corticospinal tract; PBS, phosphate-buffered saline; PFA, paraformaldehyde

.

Received January 15, 2009. Revised May 10, 2009. Accepted May 12, 2009.


*These authors contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.